U.S. Food Stock News

Wondering if New York Times stock is still worth buying after its big run, or if the easy money has already been made? Let us break down what the market is really pricing in here. The shares have climbed 4.1% over the last week, 10.4% over the past month, and are up a striking 35.3% year to date, adding to a 35.6% gain over the last year and 121.6% over three years. Some of that momentum has been fueled by ongoing enthusiasm around its growing digital subscription base and the strength of...

Earlier this month, Mizuho Securities analyst Yaron Kinar downgraded Everest Group to a hold rating, signaling a more cautious stance on the insurer. The downgrade comes from an analyst with a very strong one-year track record, which may carry extra weight in shaping investor expectations. Next, we'll assess how this high-conviction downgrade could influence Everest Group's investment narrative and risk-reward profile. Explore 28 top quantum computing companies leading the revolution in...

If you are wondering whether ZIM Integrated Shipping Services is still a bargain or if the easy money has already been made, this article will walk through what the numbers are really saying about its value. The stock has been anything but quiet lately, with shares up 2.6% over the last week, 14.9% over the past month, and 36.3% over the last year, even though it remains down 17.5% year to date. These moves have been driven in part by shifting expectations around global freight rates and...

If you are wondering whether Patterson-UTI Energy is a bargain or a value trap at today’s price, you are not alone. This breakdown is designed to give you a clear, no-jargon answer. The stock has slipped 6.1% over the last week and is down 31.7% year to date, yet it is still up 25.6% over five years. This highlights how cyclical this name can be. Recent headlines have focused on shifting North American drilling activity and ongoing consolidation in oilfield services, both of which directly...

Nuvalent (NUVL) just saw a fresh jolt of attention after veteran oncology executive Ron Squarer joined its board, a move that arrived as Wall Street sentiment toward the cancer focused biotech has turned more confident. See our latest analysis for Nuvalent. That backdrop of growing confidence is showing up in the numbers, with Nuvalent’s share price at $103.8 after a strong 90 day share price return of 35.39 percent and an impressive three year total shareholder return of 264.98 percent. This...

Earlier this month, Match Group said that CEO Spencer Rascoff will join its Board of Directors and Hinge founder Justin McLeod, now leading Overtone, will become Chairman while continuing to advise Hinge through March 2026. The move brings a founder with deep dating-app product experience and a focus on responsible, human-centered technology into Match Group’s boardroom leadership. Next, we’ll explore how Justin McLeod’s appointment as Chairman may reshape Match Group’s investment narrative...

In the past week, Credicorp reported quarterly results that surpassed expectations, supported by strong loan growth, stable asset quality, and disciplined cost control across its banking, insurance, and wealth management operations. An interesting angle is Credicorp’s rapid digital ecosystem expansion, which is widening access to underpenetrated segments while reinforcing recurring, fee-based revenue streams amid Peru’s evolving financial system. We’ll now examine how Credicorp’s...

In recent weeks, J.B. Hunt Transport Services has drawn attention as investors reacted to past stronger-than-expected Q3 2025 results and upcoming Q4 earnings, alongside active options trading that highlights growing institutional interest. What stands out is how improving productivity and cost reductions are aligning with generally positive analyst views, even as day-to-day share performance has occasionally lagged sector peers. Next, we’ll examine how this combination of upbeat earnings...

Sally Beauty Holdings recently reported quarterly revenue up 1.3% year on year, beating analyst forecasts on revenue, EBITDA and EPS, while also issuing the largest full-year guidance increase among its peers. The company extended its ongoing share repurchase program to September 30, 2029, signaling management’s confidence in its earnings power and capital allocation priorities. We’ll now explore how this guidance upgrade and earnings beat may influence Sally Beauty’s existing investment...

In recent days, ZoomInfo Technologies has attracted renewed analyst attention as BTIG initiated coverage and KeyBanc issued an upgrade, both emphasizing the company’s AI product cycle, upmarket traction, and a record near–eight-figure annual contract win. This shift in analyst sentiment highlights how ZoomInfo’s AI-led offerings and larger enterprise deals are increasingly central to its go-to-market intelligence positioning. Now we’ll explore how this AI-driven analyst optimism,...

Byline Bancorp (BY) just rolled out a fresh share repurchase program, with board approval to buy back up to 2.25 million shares, roughly 5% of the float, running through the end of 2026. See our latest analysis for Byline Bancorp. The buyback comes after a strong run, with a 14.1% 1 month share price return and a 5 year total shareholder return of 113.1%, suggesting momentum is still quietly building around a $30.51 share price. If this capital return story has your attention, it could be a...

Earlier this month, Insmed announced that its Phase 2b BiRCh trial of brensocatib in chronic rhinosinusitis without nasal polyps failed to meet all primary and secondary efficacy endpoints, prompting an immediate halt to development in this indication despite a clean safety profile. At the same time, Insmed moved to bolster its respiratory and inflammatory pipeline by acquiring INS1148, a Phase 2–ready monoclonal antibody initially aimed at interstitial lung disease and moderate-to-severe...

If you have ever looked at Generac Holdings and wondered whether the current share price really reflects its long term potential, you are not alone. This article is designed to unpack exactly that question. After a choppy run, the stock is down 13.6% over the last week and 11.1% over the past year, but still sits about 50.7% higher than three years ago. This hints at a story that is more complicated than a simple up or down trend. Recently, investors have been weighing Generac's positioning...

Wondering if Amdocs is quietly turning into a value opportunity while everyone is chasing the latest hype stock? You are not alone, and this is exactly what we are going to unpack. Despite a choppy year where the share price is down 4.4% year to date and 5.3% over the last 12 months, the stock has started to firm up recently, with a 1.4% gain over the past week and 6.8% over the last month. Much of this price action has been shaped by ongoing contract wins and renewals with major telecom...

Bullish (BLSH) has been climbing recently, with the stock up about 4% on the day and roughly 23% over the past month, even as its year to date performance remains sharply negative. See our latest analysis for Bullish. That recent 1 month share price return of about 23% looks more like a sharp rebound than a steady trend. This is especially true when set against a year to date share price return that is still deeply negative, so momentum is improving but not yet proven. If Bullish has piqued...

Marathon Petroleum (MPC) is back in focus after naming Maria A. Khoury as its next Chief Financial Officer, a leadership move that could subtly reshape how investors think about the stock. See our latest analysis for Marathon Petroleum. The CFO announcement lands after a choppy stretch, with a roughly 14% 1 month share price return decline from about $195 to $168.32, even as the 1 year total shareholder return of 29% and 5 year total shareholder return of 365.55% still point to strong long...

Rosenblatt recently initiated coverage of Taboola.com with a positive rating, highlighting the company’s AI-powered content discovery and native advertising platform that competes with major digital ad players. This endorsement comes soon after Taboola reported quarterly results that surpassed expectations and issued an upbeat outlook, reinforcing interest in its differentiated open-web advertising model. With that as context, we’ll explore how Rosenblatt’s new coverage reinforces Taboola’s...

DRDGOLD (NYSE:DRD) has flagged impending strike action at its ERGO operations from 18 December, as unions push back on wages and profit sharing. This is putting near term output and margins under closer scrutiny. See our latest analysis for DRDGOLD. Even with the strike risk grabbing headlines, DRDGOLD’s strong year to date 246.34% share price return, alongside a 261.47% one year total shareholder return, suggests momentum is still firmly on the upside as investors weigh higher operational...

Wondering if Pitney Bowes is still a bargain after its big run, or if the easy money has already been made? You are not alone, and that is exactly what we are going to unpack here. The stock is now trading around $10.62, up 3.8% over the last week, 12.0% over the past month, and 47.1% year to date, building on 51.3% returns over 1 year and 216.0% over 3 years. Those gains have come as investors have warmed to Pitney Bowes transformation story and shifting mix toward higher margin, tech...

Recent analysis suggests Xeris Biopharma Holdings (XERS) is shifting from survival mode to a profit focused specialty pharma story, with three commercial drugs and a growing pipeline reshaping how investors view the stock. See our latest analysis for Xeris Biopharma Holdings. That improving story is already showing up in the tape, with the share price at $7.34 after a 1 day share price return of 4.71 percent and a powerful year to date share price return of 112.14 percent. The 3 year total...

Toro (TTC) just delivered a quarter that cleared Wall Street’s bar, leaned on its Professional segment to do the heavy lifting, and paired the beat with upbeat guidance, dividend growth, and fresh buyback firepower. See our latest analysis for Toro. At a latest share price of $77.67, Toro has enjoyed a 1 month share price return of 13.07%, even though its 1 year total shareholder return of negative 2.71% and 3 year total shareholder return of negative 27.74% show a longer term reset in...

For investors wondering whether Under Armour at around $4.50 is a beaten-down bargain or a value trap, this breakdown outlines what the market might be overlooking. Despite a difficult longer term track record, with the share price still down 44.1% year to date and 74.0% over five years, the stock has recently bounced 4.6% over the last week and 7.1% over the last month, prompting some investors to revisit the story. Recent headlines have highlighted Under Armour refreshing its product...

Wondering if AppFolio at around $233 a share is still a smart buy, or if most of the upside is already priced in? Let us break down what the market might be implying about its long term potential. Despite being down 5.8% year to date and 7.2% over the last year, the stock has still delivered a 123.5% return over 3 years and 29.4% over 5 years, which shows that investors have rewarded the story over time, even if momentum has cooled recently. Recent interest has centered on AppFolio's...

If you are wondering whether Criteo at around $19.50 is a beaten down ad tech name or a quiet value opportunity hiding in plain sight, this piece is for you. The stock is down 4.4% over the last week, 1.9% over the last month, and a steep 50.4% year to date, compounding into a 55.1% slide over the past year that has dramatically reset expectations. Recent headlines have centered on Criteo's ongoing pivot toward a broader commerce media platform. This includes deepening retail media...